Herceptin 600 - Injection Trastuzumab - 600mg/5ml 1 Injection(s) / Injection Roche Bangladesh Pharmaceutical Introduction: Herceptin 600 is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein). Herceptin 600 is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It... Uses of Herceptin 600: Breast cancerStomach cancer Side effects of Herceptin 600: Anemia (low number of red blood cells)ChillsCommon coldCoughDecreased blood cells (red cells, white cells, and platelets)DiarrheaFatigueFeverHeadacheHeart failureInfectionInsomnia (difficulty in sleeping)Mucosal inflammationNauseaRashStomatitis (Inflammation of the mouth)Taste changeUpper respiratory tract infectionWeight loss How to use Herceptin 600: Your doctor or nurse will give you this medicine. Kindly do not self administer. How Herceptin 600 works: Herceptin 600 is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways. What if you forget to take Herceptin 600?: If you miss a dose of Herceptin 600, please consult your doctor. Indication: Breast cancer, Gastric cancer Administration: IV Administration Not for IV push or bolus administration Administer initial IV infusion over 90 min Subsequent weekly IV infusions may be administered over 30 min if prior infusions are well tolerated Adult Dose: Intravenous Breast Cancer Adjuvant treatment Indicated for adjuvant treatment of HER-2 overexpressing breast cancer Administer during and following paclitaxel, docetaxel, or docetaxel/carboplatin 4 mg/kg IV over 90 minutes, THEN 2 mg/kg IV over 30 minutes qWeek during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin) One week following the last weekly dose administer at 6 mg/kg as an IV infusion over 30?90 min every three weeks As single agent within three wk following completion of multi-modality, anthracycline based chemotherapy regimens: Initial dose at 8 mg/kg as an IV infusion over 90 min; subsequent doses at... Child Dose: Safety and efficacy not established Contraindication: Lactation (start only 6 mth after last dose of drug). Do not admin by rapid IV or bolus inj. Mode of Action: Trastuzumab, a monoclonal antibody, has action directed against a cell surface protein produced by human epidermal growth factor receptor 2 (HER2). It inhibits proliferation of tumour cells that overexpress HER2 e.g. in 1/3 of breast cancer. Precaution: Patient w/ pre-existing CV and pulmonary disease; extensive pulmonary tumour involvement. Pregnancy and lactation. Monitoring Parameters Monitor cardiac function prior and during treatment. Lactation: not known if excreted in breast milk, discontinue nursing during treatment and for 6 months after last dose Side Effect: >10% Pain (47%),Asthenia (42%),Fever (36%),Nausea (33%),Chills (32%),Cough (26%),Headache (26%),Diarrhea (25%),Vomiting (23%),Abdominal pain (22%),Back pain (22%),Dyspnea (22%),Infection (20%),Rash (18%),Anorexia (14%),Insomnia (14%),Dizziness (13%) 1-10% Flu-like syndrome (10%),Peripheral edema (10%),CHF (7%),Depression (6%),Tachycardia (5%),UTI (5%),Anemia (4%),Hypersensitivity (3%),Leukopenia (3%) Potentially Fatal: Severe hypersensitivity (anaphylaxis) and infusion reactions; pulmonary events e.g. acute respiratory distress syndrome; cardiotoxicity. Neutropenia (especially when given with chemotherapy). Interaction: Increased risk of severe cardiotoxicity with anthracyclines. Increased risk of leukopenia and anaemia in combination chemotherapy (e.g. paclitaxel). Paclitaxel may decrease the clearance of trastuzumab. Increased risk of bleeding with warfarin.